Lonza set to sell two lipid oral dosage forms sites to NextPharma
The potential acquisition will see UK CDMO NextPharma develop and broaden its technology offering into lipid-based finished dosage forms
Lonza and NextPharma have announced an agreement for the potential sale of Lonza's Ploermel (France) and Edinburgh (UK) sites which manufacture lipid oral-dose drugs as liquid-filled hard capsules and softgels.
The potential acqusition would see NextPharma, a specialized contract development and manufacturing organisation (CDMO) for oral and topical (including sterile ophthalmic) finished dosage forms, develop and broaden its technology offering into lipid-based finished dosage forms in addition to offering high potency capabilities and New Chemical Entity (NCE) development services.
The two Lonza sites, which employ around 260 and 130 permanent staff respectively, produce liquid-filled hard capsules (including Licaps) and softgels (including for high potent and hormonal products) for the pharmaceutical and consumer health and nutrition markets.
The intended divestment would see Swiss CDMO Lonza exit both softgels and liquid-filled hard capsules for the pharma market, aside from retaining capability for feasibility studies as part of a technology selection offering.
In the consumer health and nutrition space, Lonza plans to exit softgels, but continue to offer Licaps-based products (lipid capsules) out of Colmar (France), Greenwood (USA) and Sagamihara (Japan).
Capsules (including Licaps for nutrition) remain core to Lonza’s offering and the company has recently announced an investment of CHF85 million to expand capsule manufacturing capacity by 30 billion capsules annually across eight sites.
Related News
-
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance